COVID-19 is the most significant global health crisis of our lifetime.
We founded Pardes Biosciences to help stop this pandemic and prevent the next, so patients everywhere can get well sooner.
Modernizing Medicines and the Model
We are harnessing modern structure-based drug design and our tunable, reversible covalent chemistry platform to enable the discovery of new medicines for a potentially broad range of pandemic and endemic diseases – from COVID-19 to the common cold – while reimagining the patient journey to access these medicines.
Growing Our Pipeline
Our lead product candidate, PBI-0451, is an oral coronaviral protease inhibitor being developed to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. The FDA has granted PBI-0451 Fast Track designation, and we have begun enrolling patients in a Phase 2 clinical trial. Beyond our lead program we are cultivating our research to grow a pipeline of potential drug candidates.
Join Us. Change Medicine.
The pandemic changed everything. Join us in cultivating and harvesting the fruits of systemic change, as we reimagine the model for bringing new medicines to patients.
Follow the latest news as we grow our team, advance our science, work to solve pandemic-sized problems, and cultivate the change we want to see in our industry.